These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19052038)

  • 1. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
    Nakagawa K; Minami H; Kanezaki M; Mukaiyama A; Minamide Y; Uejima H; Kurata T; Nogami T; Kawada K; Mukai H; Sasaki Y; Fukuoka M
    Jpn J Clin Oncol; 2009 Feb; 39(2):116-23. PubMed ID: 19052038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
    Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
    Burris HA
    Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
    Burris HA; Taylor CW; Jones SF; Koch KM; Versola MJ; Arya N; Fleming RA; Smith DA; Pandite L; Spector N; Wilding G
    Clin Cancer Res; 2009 Nov; 15(21):6702-8. PubMed ID: 19825948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.
    Wang MN; Kuang Y; Gong LY; Hua Y; Pei Q; Guo CX; Cao Y; Huang J; Yang GP
    Invest New Drugs; 2020 Dec; 38(6):1826-1835. PubMed ID: 32535812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
    Holden SN; Eckhardt SG; Basser R; de Boer R; Rischin D; Green M; Rosenthal MA; Wheeler C; Barge A; Hurwitz HI
    Ann Oncol; 2005 Aug; 16(8):1391-7. PubMed ID: 15905307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
    Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
    Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
    Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
    Inada-Inoue M; Ando Y; Kawada K; Mitsuma A; Sawaki M; Yokoyama T; Sunakawa Y; Ishida H; Araki K; Yamashita K; Mizuno K; Nagashima F; Takekura A; Nagamatsu K; Sasaki Y
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):673-83. PubMed ID: 24464355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
    Iwata H; Fujii H; Masuda N; Mukai H; Nishimura Y; Katsura K; Ellis CE; Gagnon RC; Nakamura S
    Breast Cancer; 2015 Mar; 22(2):192-200. PubMed ID: 23689990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
    Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
    Bence AK; Anderson EB; Halepota MA; Doukas MA; DeSimone PA; Davis GA; Smith DA; Koch KM; Stead AG; Mangum S; Bowen CJ; Spector NL; Hsieh S; Adams VR
    Invest New Drugs; 2005 Jan; 23(1):39-49. PubMed ID: 15528979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.